Bruce G. Allen Investments LLC Purchases Shares of 249 Becton, Dickinson and Company (NYSE:BDX)

Bruce G. Allen Investments LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDXFree Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 249 shares of the medical instruments supplier’s stock, valued at approximately $61,000.

Other hedge funds have also bought and sold shares of the company. Moneta Group Investment Advisors LLC lifted its position in shares of Becton, Dickinson and Company by 95,813.8% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 4,045,643 shares of the medical instruments supplier’s stock valued at $1,028,807,000 after buying an additional 4,041,425 shares during the last quarter. Norges Bank acquired a new stake in Becton, Dickinson and Company during the 4th quarter valued at $697,398,000. Osaic Holdings Inc. boosted its position in Becton, Dickinson and Company by 1,353.9% during the second quarter. Osaic Holdings Inc. now owns 1,680,292 shares of the medical instruments supplier’s stock worth $31,207,000 after purchasing an additional 1,564,723 shares during the period. Ontario Teachers Pension Plan Board increased its holdings in shares of Becton, Dickinson and Company by 242.8% in the third quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock valued at $461,158,000 after purchasing an additional 1,263,391 shares during the last quarter. Finally, PineStone Asset Management Inc. raised its position in shares of Becton, Dickinson and Company by 262.0% in the third quarter. PineStone Asset Management Inc. now owns 847,448 shares of the medical instruments supplier’s stock valued at $219,091,000 after purchasing an additional 613,369 shares during the period. 86.72% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BDX has been the subject of several research analyst reports. Barclays lifted their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Morgan Stanley lowered their target price on Becton, Dickinson and Company from $310.00 to $280.00 and set an “overweight” rating on the stock in a research note on Monday, December 4th. Finally, Raymond James lifted their price target on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $279.17.

Get Our Latest Stock Report on Becton, Dickinson and Company

Insider Transactions at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Up 1.1 %

Shares of NYSE BDX opened at $240.24 on Wednesday. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. The company has a market cap of $69.41 billion, a price-to-earnings ratio of 56.93, a PEG ratio of 1.96 and a beta of 0.42. Becton, Dickinson and Company has a 12 month low of $229.85 and a 12 month high of $287.32. The stock has a 50-day moving average price of $238.38 and a two-hundred day moving average price of $246.05.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last issued its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, topping the consensus estimate of $2.39 by $0.29. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.73 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.98 earnings per share. As a group, analysts forecast that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 1.58%. The ex-dividend date of this dividend is Thursday, March 7th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 90.05%.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Further Reading

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.